The FDA approved 100 abbreviated new drug applications (ANDAs) through its congressionally established Competitive Generic Therapy (CGT) pathway in 2021, bringing 100 new low-priced medicines to the market for originator drugs that the agency had deemed to have inadequate generic competition.
Source: Drug Industry Daily